Chiesi announces the departure of Ugo Di Francesco as CEO of the Group
31 Agosto 2022
First carbon minimal pMDI is on track with the goal to benefit patients and planet
27 Luglio 2022
Chiesi tracks actions taken for a healthier, more sustainable future
14 Luglio 2022
Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH
02 Maggio 2022
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease
07 Aprile 2022
Chiesi Group continues to grow
31 Marzo 2022
Koura opens world’s first HFA 152a medical propellant production facility
30 Marzo 2022
Solidarity actions to support the people affected by the war
08 Aprile 2022
Chiesi France receives Choose France’s “Contribution au plan de relance (Contribution to Stimulus Plan)” special award from the Minister for Territorial Cohesion and Relations with Local Authorities
19 Gennaio 2022
A new clinical framework redefines the diagnosis of COPD Exacerbations
